This article was originally published in The Tan Sheet
Executive SummaryConsumer Healthcare sales grew 2% in 2005 to reach $5.46 bil. for the year, GlaxoSmithKline announces Feb. 8. OTC drug sales were up 1% to $2.4 bil. (£ = $1.74), with growth in analgesics up 5% and respiratory tract drugs up 6%. The consumer division's September sale of five U.S. prescription dermatologicals contributed to a 12% drop in sales for the unit. The firm is "absolutely confident" that its Consumer division can continue to increase operating margins, CEO J.P. Garnier stated during an earnings call. The comment was a response to a question about whether the division's operating margins, which have increased from 20% to 24% in recent years, are sustainable. "I think what's going to affect margin is the overall revenue growth of the consumer business in '06," Garnier stated. "But we do have a number of programs where actually we convert cost saving from manufacturing and SG&A into more promotion because promotion drives the sales line in this business." The firm is awaiting an FDA decision on the proposed OTC sale of Alli (orlistat 60 mg)...
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Laparoscopic power morcellation to remove uterine fibroids should only be performed with the use of a compatible containment system, and only on women younger than 50, the US FDA said in a newly published safety communication and draft guidance document. See what the president of the gynecologic trade group AAGL, Jubilee Brown, said about it here.